1
|
Ben Hassine K, Ceppi F, Baleydier F, Von Bueren AO, Beck Popovic M, Ansari M. [Precision medicine in the treatment of pediatric cancers]. Rev Med Suisse 2023; 19:380-387. [PMID: 36815329 DOI: 10.53738/revmed.2023.19.815.380] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/18/2023]
Abstract
Despite the progress in cure rates for pediatric cancers, several challenges remain, such as the management of diseases with poor prognosis. The efficacy of intensified chemotherapies is also accompanied by increased risks of severe acute and chronic toxicities. Thus, therapies specifically targeting tumor cells, or inhibiting oncogenic molecular aberrations, could provide more effective and less toxic treatments for pediatric cancers. Personalization of chemotherapies through pharmacogenetics and precision dosing could also improve the efficacy and toxicity of chemotherapies. In this review, we describe precision medicine strategies implemented or undergoing clinical evaluation in the treatment of pediatric cancers.
Collapse
Affiliation(s)
- Khalil Ben Hassine
- Plateforme de recherche CANSEARCH en oncologie et hématologie pédiatrique, Faculté de médecine, Département de la femme, de l'enfant et de l'adolescent, Université de Genève, Centre médical universitaire, 1206 Genève
| | - Francesco Ceppi
- Unité d'hématologie-oncologie pédiatrique, Service de pédiatrie, Département Femme-mère-enfant, Centre hospitalier universitaire vaudois et Université de Lausanne, 1011 Lausanne
| | - Frederic Baleydier
- Plateforme de recherche CANSEARCH en oncologie et hématologie pédiatrique, Faculté de médecine, Département de la femme, de l'enfant et de l'adolescent, Université de Genève, Centre médical universitaire, 1206 Genève
- Unité d'oncologie et hématologie pédiatrique, Département de la femme, de l'enfant et de l'adolescent, Hôpitaux universitaires de Genève, 1211 Genève 14
| | - André O Von Bueren
- Plateforme de recherche CANSEARCH en oncologie et hématologie pédiatrique, Faculté de médecine, Département de la femme, de l'enfant et de l'adolescent, Université de Genève, Centre médical universitaire, 1206 Genève
- Unité d'oncologie et hématologie pédiatrique, Département de la femme, de l'enfant et de l'adolescent, Hôpitaux universitaires de Genève, 1211 Genève 14
| | - Maja Beck Popovic
- Unité d'hématologie-oncologie pédiatrique, Service de pédiatrie, Département Femme-mère-enfant, Centre hospitalier universitaire vaudois et Université de Lausanne, 1011 Lausanne
| | - Marc Ansari
- Plateforme de recherche CANSEARCH en oncologie et hématologie pédiatrique, Faculté de médecine, Département de la femme, de l'enfant et de l'adolescent, Université de Genève, Centre médical universitaire, 1206 Genève
- Unité d'oncologie et hématologie pédiatrique, Département de la femme, de l'enfant et de l'adolescent, Hôpitaux universitaires de Genève, 1211 Genève 14
| |
Collapse
|
2
|
Waespe N, Strebel S, Nava T, Uppugunduri CRS, Marino D, Mattiello V, Otth M, Gumy-Pause F, Von Bueren AO, Baleydier F, Mader L, Spoerri A, Kuehni CE, Ansari M. Cohort-based association study of germline genetic variants with acute and chronic health complications of childhood cancer and its treatment: Genetic Risks for Childhood Cancer Complications Switzerland (GECCOS) study protocol. BMJ Open 2022; 12:e052131. [PMID: 35074812 PMCID: PMC8788194 DOI: 10.1136/bmjopen-2021-052131] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
Abstract
INTRODUCTION Childhood cancer and its treatment may lead to various health complications. Related impairment in quality of life, excess in deaths and accumulated healthcare costs are relevant. Genetic variations are suggested to contribute to the wide inter-individual variability of complications but have been used only rarely to risk-stratify treatment and follow-up care. This study aims to identify germline genetic variants associated with acute and late complications of childhood cancer. METHODS AND ANALYSIS The Genetic Risks for Childhood Cancer Complications Switzerland (GECCOS) study is a nationwide cohort study. Eligible are patients and survivors who were diagnosed with childhood cancers or Langerhans cell histiocytosis before age 21 years, were registered in the Swiss Childhood Cancer Registry (SCCR) since 1976 and have consented to the Paediatric Biobank for Research in Haematology and Oncology, Geneva, host of the national Germline DNA Biobank Switzerland for Childhood Cancer and Blood Disorders (BISKIDS).GECCOS uses demographic and clinical data from the SCCR and the associated Swiss Childhood Cancer Survivor Study. Clinical outcome data consists of organ function testing, health conditions diagnosed by physicians, second primary neoplasms and self-reported information from participants. Germline genetic samples and sequencing data are collected in BISKIDS. We will perform association analyses using primarily whole-exome or whole-genome sequencing to identify genetic variants associated with specified health conditions. We will use clustering and machine-learning techniques and assess multiple health conditions in different models. DISCUSSION GECCOS will improve knowledge of germline genetic variants associated with childhood cancer-associated health conditions and help to further individualise cancer treatment and follow-up care, potentially resulting in improved efficacy and reduced side effects. ETHICS AND DISSEMINATION The Geneva Cantonal Commission for Research Ethics has approved the GECCOS study.Research findings will be disseminated through national and international conferences, publications in peer-reviewed journals and in lay language online. TRIAL REGISTRATION NUMBER NCT04702321.
Collapse
Affiliation(s)
- Nicolas Waespe
- CANSEARCH Research Platform for Paediatric Oncology and Haematology, Department of Pediatrics, Gynecology and Obstetrics, Faculty of Medicine, University of Geneva, Geneva, Switzerland
- Childhood Cancer Research Group, Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
- Graduate School for Cellular and Biomedical Sciences (GCB), University of Bern, Bern, Switzerland
- Division of Paediatric Oncology and Haematology, Department of Paediatrics, Inselspital, Bern University Hospital, Bern, Switzerland
| | - Sven Strebel
- CANSEARCH Research Platform for Paediatric Oncology and Haematology, Department of Pediatrics, Gynecology and Obstetrics, Faculty of Medicine, University of Geneva, Geneva, Switzerland
- Childhood Cancer Research Group, Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
- Graduate School for Health Sciences (GHS), University of Bern, Bern, Switzerland
| | - Tiago Nava
- CANSEARCH Research Platform for Paediatric Oncology and Haematology, Department of Pediatrics, Gynecology and Obstetrics, Faculty of Medicine, University of Geneva, Geneva, Switzerland
- Division of Paediatric Oncology and Haematology, Department of Women, Children, and Adolescents, University Hospitals of Geneva, Geneve, Switzerland
| | - Chakradhara Rao S Uppugunduri
- CANSEARCH Research Platform for Paediatric Oncology and Haematology, Department of Pediatrics, Gynecology and Obstetrics, Faculty of Medicine, University of Geneva, Geneva, Switzerland
| | - Denis Marino
- CANSEARCH Research Platform for Paediatric Oncology and Haematology, Department of Pediatrics, Gynecology and Obstetrics, Faculty of Medicine, University of Geneva, Geneva, Switzerland
| | - Veneranda Mattiello
- CANSEARCH Research Platform for Paediatric Oncology and Haematology, Department of Pediatrics, Gynecology and Obstetrics, Faculty of Medicine, University of Geneva, Geneva, Switzerland
- Division of Paediatric Oncology and Haematology, Department of Women, Children, and Adolescents, University Hospitals of Geneva, Geneve, Switzerland
| | - Maria Otth
- Childhood Cancer Research Group, Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
- Graduate School for Cellular and Biomedical Sciences (GCB), University of Bern, Bern, Switzerland
- Division of Oncology-Hematology, Department of Pediatrics, Kantonsspital Aarau AG, Aarau, Switzerland
| | - Fabienne Gumy-Pause
- CANSEARCH Research Platform for Paediatric Oncology and Haematology, Department of Pediatrics, Gynecology and Obstetrics, Faculty of Medicine, University of Geneva, Geneva, Switzerland
- Division of Paediatric Oncology and Haematology, Department of Women, Children, and Adolescents, University Hospitals of Geneva, Geneve, Switzerland
| | - André O Von Bueren
- CANSEARCH Research Platform for Paediatric Oncology and Haematology, Department of Pediatrics, Gynecology and Obstetrics, Faculty of Medicine, University of Geneva, Geneva, Switzerland
- Division of Paediatric Oncology and Haematology, Department of Women, Children, and Adolescents, University Hospitals of Geneva, Geneve, Switzerland
| | - Frederic Baleydier
- CANSEARCH Research Platform for Paediatric Oncology and Haematology, Department of Pediatrics, Gynecology and Obstetrics, Faculty of Medicine, University of Geneva, Geneva, Switzerland
- Division of Paediatric Oncology and Haematology, Department of Women, Children, and Adolescents, University Hospitals of Geneva, Geneve, Switzerland
| | - Luzius Mader
- Childhood Cancer Research Group, Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
| | - Adrian Spoerri
- SwissRDL - Medical Registries and Data Linkage, Institute of Social and Preventive Medicine, Universitat Bern, Bern, Switzerland
| | - Claudia E Kuehni
- Childhood Cancer Research Group, Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
- Division of Paediatric Oncology and Haematology, Department of Paediatrics, Inselspital, Bern University Hospital, Bern, Switzerland
| | - Marc Ansari
- CANSEARCH Research Platform for Paediatric Oncology and Haematology, Department of Pediatrics, Gynecology and Obstetrics, Faculty of Medicine, University of Geneva, Geneva, Switzerland
- Division of Paediatric Oncology and Haematology, Department of Women, Children, and Adolescents, University Hospitals of Geneva, Geneve, Switzerland
| |
Collapse
|
3
|
Leclercq C, Toutain F, Baleydier F, L'Huillier AG, Wagner N, Lironi C, Calza AM, Ansari M, Blanchard-Rohner G. Pediatric Acute B-Cell Lymphoblastic Leukemia Developing Following Recent SARS-CoV-2 Infection. J Pediatr Hematol Oncol 2021; 43:e1177-e1180. [PMID: 33480653 DOI: 10.1097/mph.0000000000002064] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/31/2020] [Accepted: 12/11/2020] [Indexed: 11/25/2022]
Abstract
Coronavirus disease-2019 in children has been linked to various clinical presentation, from paucisymptomatic cutaneous eruptions, to multisystemic inflammatory syndrome. We report the case of an 8-year-old boy who presented with persistent fever and pancytopenia, associated to a skin rash. An extensive etiological workup showed a positive serology for severe acute respiratory syndrome coronavirus 2 and Epstein-Barr virus. A few weeks later, type B acute lymphocytic leukemia was diagnosed. This case underlines the polymorphic appearance of coronavirus disease-2019 and the need for critical appraisal.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | - Geraldine Blanchard-Rohner
- Paediatric Immunology and Vaccinology Unit, Geneva University Hospitals and Faculty of Medicine
- Center of Vaccinology, Geneva University Hospitals, Geneva, Switzerland
| |
Collapse
|
4
|
Baleydier F, Bernard F, Ansari M. The Possibilities of Immunotherapy for Children with Primary Immunodeficiencies Associated with Cancers. Biomolecules 2020; 10:biom10081112. [PMID: 32731356 PMCID: PMC7464796 DOI: 10.3390/biom10081112] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2020] [Revised: 07/12/2020] [Accepted: 07/24/2020] [Indexed: 12/13/2022] Open
Abstract
Many primary immunodeficiencies (PIDs) are recognised as being associated with malignancies, particularly lymphoid malignancies, which represent the highest proportion of cancers occurring in conjunction with this underlying condition. When patients present with genetic errors of immunity, clinicians must often reflect on whether to manage antitumoral treatment conventionally or to take a more personalised approach, considering possible existing comorbidities and the underlying status of immunodeficiency. Recent advances in antitumoral immunotherapies, such as monoclonal antibodies, antigen-specific adoptive cell therapies or compounds with targeted effects, potentially offer significant opportunities for optimising treatment for those patients, especially with lymphoid malignancies. In cases involving PIDs, variable oncogenic mechanisms exist, and opportunities for antitumoral immunotherapies can be considered accordingly. In cases involving a DNA repair defect or genetic instability, monoclonal antibodies can be proposed instead of chemotherapy to avoid severe toxicity. Malignancies secondary to uncontrolled virus-driven proliferation or the loss of antitumoral immunosurveillance may benefit from antivirus cell therapies or allogeneic stem cell transplantation in order to restore the immune antitumoral caretaker function. A subset of PIDs is caused by gene defects affecting targetable signalling pathways directly involved in the oncogenic process, such as the constitutive activation of phosphoinositol 3-kinase/protein kinase B (PI3K/AKT) in activated phosphoinositide 3-kinase delta syndrome (APDS), which can be settled with PI3K/AKT inhibitors. Therefore, immunotherapy provides clinicians with interesting antitumoral therapeutic weapons to treat malignancies when there is an underlying PID.
Collapse
Affiliation(s)
- Frederic Baleydier
- Department for Women, Children and Adolescents, Paediatric Haemato-Oncology unit, Geneva University Hospital, CH-1211 Geneva, Switzerland; (F.B.); (M.A.)
- CANSEARCH research laboratory, Medical Faculty, Geneva University, 1205 Geneva, Switzerland
- Correspondence: ; Tel.: +41-79-55-34-221; Fax: +41-22-37-24-720
| | - Fanette Bernard
- Department for Women, Children and Adolescents, Paediatric Haemato-Oncology unit, Geneva University Hospital, CH-1211 Geneva, Switzerland; (F.B.); (M.A.)
- CANSEARCH research laboratory, Medical Faculty, Geneva University, 1205 Geneva, Switzerland
| | - Marc Ansari
- Department for Women, Children and Adolescents, Paediatric Haemato-Oncology unit, Geneva University Hospital, CH-1211 Geneva, Switzerland; (F.B.); (M.A.)
- CANSEARCH research laboratory, Medical Faculty, Geneva University, 1205 Geneva, Switzerland
| |
Collapse
|
5
|
Teuma C, Pelletier S, Toussaint F, Rabeyrin M, Nicolini FE, Fouque D, Baleydier F. Membranous glomerulonephritis as a novel paraneoplastic syndrome in a young man with chronic myeloid leukemia. Leuk Lymphoma 2015; 57:483-485. [PMID: 26062944 DOI: 10.3109/10428194.2015.1061188] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Affiliation(s)
- Cécile Teuma
- a Department of Nephrology , Hospices Civils de Lyon, Centre Hospitalier Lyon Sud , Pierre-Bénite , France
| | - Solenne Pelletier
- a Department of Nephrology , Hospices Civils de Lyon, Centre Hospitalier Lyon Sud , Pierre-Bénite , France
| | - Francine Toussaint
- b Department of Paediatric Haemato-oncology , Bristol Royal Hospital for Children, University Hospitals Bristol , Bristol , UK
| | - Maud Rabeyrin
- c Pathology department, Hospices Civils de Lyon , Hôpital Edouard Herriot , Lyon , France
| | - Franck E Nicolini
- d Hematology department 1G , Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre Bénite & INSERM U1052, CRCL , Lyon , France
| | - Denis Fouque
- a Department of Nephrology , Hospices Civils de Lyon, Centre Hospitalier Lyon Sud , Pierre-Bénite , France.,b Department of Paediatric Haemato-oncology , Bristol Royal Hospital for Children, University Hospitals Bristol , Bristol , UK.,c Pathology department, Hospices Civils de Lyon , Hôpital Edouard Herriot , Lyon , France.,d Hematology department 1G , Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre Bénite & INSERM U1052, CRCL , Lyon , France.,e Carmen, Cens, Université de Lyon , Lyon , France
| | - Frederic Baleydier
- f Paediatric Haematology, Institut Hematologie et Oncologie Pediatrique, Hospices Civils de Lyon, Groupement Hospitalier Est , France
| |
Collapse
|
6
|
Gutierrez A, Pan L, Groen R, Baleydier F, Kentsis A, Marineau J, Grebliunaite R, Kozakewich E, Reed C, Pflumio F, Poglio S, Uzan B, Clemons P, Verplank L, An F, Burbank J, Norton S, Tolliday N, Steen H, Weng AP, Yuan H, Bradner JE, Mitsiades C, Look AT, Aster JC. Abstract IA8: A new class of drugs active in T-ALL is revealed in a zebrafish screen. Mol Cancer Res 2014. [DOI: 10.1158/1557-3125.modorg-ia8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive cancer frequently associated with activating NOTCH1 mutations and dysregulation of MYC. We performed two complementary screens to identify novel agents with activity against T-ALL: i) a zebrafish screen for small molecules toxic to MYC-overexpressing thymocytes, and ii) a human T-ALL cell line screen for small molecules that synergize with Notch inhibitors. “Hits” common to both screens included perphenazine, a phenothiazine antipsychotic that induced apoptosis of fish, mouse, and human T-ALL cells. Using ligand-affinity chromatography coupled to mass spectrometry, we identified protein phosphatase 2A (PP2A) as the critical perphenazine target. In line with this finding, T-ALL cell lines treated with perphenazine underwent apoptosis associated with rapid dephosphorylation of multiple PP2A substrates, indicating that perphenazine binds and activates the PP2A tumor supressor. Moreover, shRNA knockdown of the scaffolding or catalytic subunits of PP2A attenuated the activity of perphenazine, indicating that PP2A is required for its antileukemic activity. Finally, treatment of primary human T-ALLs with pherphenazine suppressed cell growth and caused dephosphorylated of PP2A targets in vitro and in vivo. Our findings provide a mechanistic explanation for the recurrent “rediscovery” of phenothiazines as a class of drugs with anti-cancer effects and highlight the therapeutic potential of pharmacologic PP2A activation in T-ALL and other cancers driven by hyperphosphorylated PP2A substrates.
Citation Format: Alejandro Gutierrez, Li Pan, Richard Groen, Frederic Baleydier, Alex Kentsis, Jason Marineau, Ruta Grebliunaite, Elena Kozakewich, Casie Reed, Francoise Pflumio, Sandrine Poglio, Benjamin Uzan, Paul Clemons, Lynn Verplank, Frank An, Jason Burbank, Stephanie Norton, Nicola Tolliday, Hanno Steen, Andrew P. Weng, Huipin Yuan, James E. Bradner, Constantine Mitsiades, A. Thomas Look, Jon C. Aster. A new class of drugs active in T-ALL is revealed in a zebrafish screen. [abstract]. In: Proceedings of the AACR Special Conference: The Translational Impact of Model Organisms in Cancer; Nov 5-8, 2013; San Diego, CA. Philadelphia (PA): AACR; Mol Cancer Res 2014;12(11 Suppl):Abstract nr IA8.
Collapse
Affiliation(s)
- Alejandro Gutierrez
- 1Dana-Farber Cancer Institute, Boston, MA,
- 5Boston Children's Hospital, Boston, MA,
| | - Li Pan
- 2Brigham & Women's Hospital, Boston, MA,
| | - Richard Groen
- 1Dana-Farber Cancer Institute, Boston, MA,
- 8University of Utrecht, Utrecht, Netherlands,
| | - Frederic Baleydier
- 2Brigham & Women's Hospital, Boston, MA,
- 9Hospices Civils de Lyon, Lyon, France,
| | - Alex Kentsis
- 1Dana-Farber Cancer Institute, Boston, MA,
- 5Boston Children's Hospital, Boston, MA,
| | | | | | | | - Casie Reed
- 1Dana-Farber Cancer Institute, Boston, MA,
| | - Francoise Pflumio
- 3Institut National de la Santé et de la Recherche Médicale, Fontenay-aux-Roses and Université Paris-Sud, Fontenay-aux-Roses, France,
- 10Université Paris-Diderot, Paris, France
| | - Sandrine Poglio
- 3Institut National de la Santé et de la Recherche Médicale, Fontenay-aux-Roses and Université Paris-Sud, Fontenay-aux-Roses, France,
- 10Université Paris-Diderot, Paris, France
| | - Benjamin Uzan
- 3Institut National de la Santé et de la Recherche Médicale, Fontenay-aux-Roses and Université Paris-Sud, Fontenay-aux-Roses, France,
- 10Université Paris-Diderot, Paris, France
| | | | | | - Frank An
- 4Broad Institute, Cambridge, MA,
| | | | | | | | | | | | - Huipin Yuan
- 7University of Twente, Enschede, Netherlands,
| | | | | | - A. Thomas Look
- 1Dana-Farber Cancer Institute, Boston, MA,
- 5Boston Children's Hospital, Boston, MA,
| | | |
Collapse
|
7
|
Cahu X, Calvo J, Prade N, Poglio S, Uzan B, Leblanc T, Baruchel A, Landman-Parker J, Petit A, Baleydier F, Ballerini P, Ghysdael J, Delabesse E, Pflumio F. Declined Presentation. Exp Hematol 2014. [DOI: 10.1016/j.exphem.2014.07.093] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
8
|
Mendes-da-Cruz DA, Brignier AC, Asnafi V, Baleydier F, Messias CV, Lepelletier Y, Bedjaoui N, Renand A, Smaniotto S, Canioni D, Milpied P, Balabanian K, Bousso P, Leprêtre S, Bertrand Y, Dombret H, Ifrah N, Dardenne M, Macintyre E, Savino W, Hermine O. Semaphorin 3F and neuropilin-2 control the migration of human T-cell precursors. PLoS One 2014; 9:e103405. [PMID: 25068647 PMCID: PMC4113369 DOI: 10.1371/journal.pone.0103405] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2014] [Accepted: 07/01/2014] [Indexed: 01/21/2023] Open
Abstract
Neuropilins and semaphorins are known as modulators of axon guidance, angiogenesis, and organogenesis in the developing nervous system, but have been recently evidenced as also playing a role in the immune system. Here we describe the expression and role of semaphorin 3F (SEMA3F) and its receptor neuropilin-2 (NRP2) in human T cell precursors. NRP2 and SEMA3F are expressed in the human thymus, in both lymphoid and non-lymphoid compartments. SEMA3F have a repulsive effect on thymocyte migration and inhibited CXCL12- and sphingosine-1-phosphate (S1P)-induced thymocyte migration by inhibiting cytoskeleton reorganization prior to stimuli. Moreover, NRP2 and SEMA3F are expressed in human T-cell acute lymphoblastic leukemia/lymphoma primary cells. In these tumor cells, SEMA3F also blocks their migration induced by CXCL12 and S1P. Our data show that SEMA3F and NRP2 are further regulators of human thymocyte migration in physiological and pathological conditions.
Collapse
Affiliation(s)
- Daniella Arêas Mendes-da-Cruz
- CNRS UMR8147, Paris Descartes University, Paris, France
- Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil
- * E-mail: (DAMC); (OH)
| | - Anne Colette Brignier
- CNRS UMR8147, Paris Descartes University, Paris, France
- Department of Clinical Hematology, Necker Children's Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
| | - Vahid Asnafi
- Laboratory of Oncohematology, AP-HP, Necker Children's Hospital, INSERM U1151, Paris, France
| | - Frederic Baleydier
- Laboratory of Oncohematology, AP-HP, Necker Children's Hospital, INSERM U1151, Paris, France
| | | | - Yves Lepelletier
- CNRS UMR8147, Paris Descartes University, Paris, France
- INSERM U1163, CNRS ERL 8254, Laboratory of cellular and molecular basis of hematological disorders and their therapeutic implications, Imagine Institute, Paris, France
| | - Nawel Bedjaoui
- Laboratory of Oncohematology, AP-HP, Necker Children's Hospital, INSERM U1151, Paris, France
| | - Amedée Renand
- CNRS UMR8147, Paris Descartes University, Paris, France
| | - Salete Smaniotto
- Department of Morphology, Federal University of Alagoas, Maceió, Brazil
| | - Danielle Canioni
- Laboratory of Oncohematology, AP-HP, Necker Children's Hospital, INSERM U1151, Paris, France
- Department of Morphology, Federal University of Alagoas, Maceió, Brazil
| | | | | | | | | | - Yves Bertrand
- Service of Pediatric Hematology, Hôpital Debrousse, Lyon, France
| | - Hervé Dombret
- University Paris 7, Hôpital Saint-Louis, AP-HP, and Institut Universitaire d'Hématologie EA3518, Paris, France
| | - Norbert Ifrah
- Pôle de Recherche et d'Enseignement Supérieur l'Université Nantes Angers Le Mans, Centre Hospitalier Universitaire Angers, Service des Maladies du Sang and INSERM U892, Angers, France
| | | | - Elizabeth Macintyre
- Laboratory of Oncohematology, AP-HP, Necker Children's Hospital, INSERM U1151, Paris, France
| | - Wilson Savino
- Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil
| | - Olivier Hermine
- CNRS UMR8147, Paris Descartes University, Paris, France
- Laboratory of Oncohematology, AP-HP, Necker Children's Hospital, INSERM U1151, Paris, France
- INSERM U1163, CNRS ERL 8254, Laboratory of cellular and molecular basis of hematological disorders and their therapeutic implications, Imagine Institute, Paris, France
- * E-mail: (DAMC); (OH)
| |
Collapse
|
9
|
Gutierrez A, Pan L, Groen RWJ, Baleydier F, Kentsis A, Marineau J, Grebliunaite R, Kozakewich E, Reed C, Pflumio F, Poglio S, Uzan B, Clemons P, VerPlank L, An F, Burbank J, Norton S, Tolliday N, Steen H, Weng AP, Yuan H, Bradner JE, Mitsiades C, Look AT, Aster JC. Phenothiazines induce PP2A-mediated apoptosis in T cell acute lymphoblastic leukemia. J Clin Invest 2014; 124:644-55. [PMID: 24401270 DOI: 10.1172/jci65093] [Citation(s) in RCA: 160] [Impact Index Per Article: 16.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2013] [Accepted: 10/30/2013] [Indexed: 12/15/2022] Open
Abstract
T cell acute lymphoblastic leukemia (T-ALL) is an aggressive cancer that is frequently associated with activating mutations in NOTCH1 and dysregulation of MYC. Here, we performed 2 complementary screens to identify FDA-approved drugs and drug-like small molecules with activity against T-ALL. We developed a zebrafish system to screen small molecules for toxic activity toward MYC-overexpressing thymocytes and used a human T-ALL cell line to screen for small molecules that synergize with Notch inhibitors. We identified the antipsychotic drug perphenazine in both screens due to its ability to induce apoptosis in fish, mouse, and human T-ALL cells. Using ligand-affinity chromatography coupled with mass spectrometry, we identified protein phosphatase 2A (PP2A) as a perphenazine target. T-ALL cell lines treated with perphenazine exhibited rapid dephosphorylation of multiple PP2A substrates and subsequent apoptosis. Moreover, shRNA knockdown of specific PP2A subunits attenuated perphenazine activity, indicating that PP2A mediates the drug's antileukemic activity. Finally, human T-ALLs treated with perphenazine exhibited suppressed cell growth and dephosphorylation of PP2A targets in vitro and in vivo. Our findings provide a mechanistic explanation for the recurring identification of phenothiazines as a class of drugs with anticancer effects. Furthermore, these data suggest that pharmacologic PP2A activation in T-ALL and other cancers driven by hyperphosphorylated PP2A substrates has therapeutic potential.
Collapse
|
10
|
Callens C, Baleydier F, Lengline E, Ben Abdelali R, Petit A, Villarese P, Cieslak A, Minard-Colin V, Rullier A, Moreau A, Baruchel A, Schmitt C, Asnafi V, Bertrand Y, Macintyre E. Clinical impact of NOTCH1 and/or FBXW7 mutations, FLASH deletion, and TCR status in pediatric T-cell lymphoblastic lymphoma. J Clin Oncol 2012; 30:1966-73. [PMID: 22547598 DOI: 10.1200/jco.2011.39.7661] [Citation(s) in RCA: 98] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023] Open
Abstract
PURPOSE Pediatric T-cell lymphoblastic lymphomas (T-LBL) are commonly treated on T-cell acute lymphoblastic leukemia (T-ALL) -derived protocols. Therapeutic stratification based on response to the prephase treatment and on minimal residual disease assessment is well established in T-ALL but is not easy to extrapolate to T-LBL. The identification of molecular prognostic markers at diagnosis in T-LBL could provide an alternative for early therapeutic stratification. Our study determines the frequency and prognostic value of NOTCH1/FBXW7 mutations (N/F(mut)), FLASH deletion at chromosome 6q, and TCR rearrangements in a prospective cohort of pediatric T-LBL. PATIENTS AND METHODS Pathologic samples were obtained at diagnosis for 54 patients treated according to the EuroLB02 protocol in France. N/F(mut) were identified by direct sequencing and allelic dosage was used to detect FLASH and TCRγ deletions, which were interpreted in conjunction with TCRγ, TCRβ, and TCRδ rearrangements. RESULTS N/F(mut) were found in 55% of T-LBL patients, in whom they were associated with improved event-free survival (P < .01) and overall survival (P < .01). FLASH monoallelic deletions were observed in 18% of patients; they were predominantly N/F wild-type (six of nine) and tended to be of inferior prognosis (P = .09). Absence of biallelic TCRγ deletion (ABD) was seen in 7%, all of which were N/F(mut) and identified a poor prognosis group (P = .02). On multivariate analysis of N/F(mut), TCRγ ABD, and FLASH deletion, only N/F(mut) was an independent factor for good prognosis. CONCLUSION Mutational status of NOTCH1/FBXW7 represents a promising marker for early therapeutic stratification in pediatric T-LBL.
Collapse
|
11
|
Aste-Amézaga M, Zhang N, Lineberger JE, Arnold BA, Toner TJ, Gu M, Huang L, Vitelli S, Vo KT, Haytko P, Zhao JZ, Baleydier F, L'Heureux S, Wang H, Gordon WR, Thoryk E, Andrawes MB, Tiyanont K, Stegmaier K, Roti G, Ross KN, Franlin LL, Wang H, Wang F, Chastain M, Bett AJ, Audoly LP, Aster JC, Blacklow SC, Huber HE. Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptors. PLoS One 2010; 5:e9094. [PMID: 20161710 PMCID: PMC2817004 DOI: 10.1371/journal.pone.0009094] [Citation(s) in RCA: 141] [Impact Index Per Article: 10.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2009] [Accepted: 12/30/2009] [Indexed: 01/16/2023] Open
Abstract
Background Notch receptors normally play a key role in guiding a variety of cell fate decisions during development and differentiation of metazoan organisms. On the other hand, dysregulation of Notch1 signaling is associated with many different types of cancer as well as tumor angiogenesis, making Notch1 a potential therapeutic target. Principal Findings Here we report the in vitro activities of inhibitory Notch1 monoclonal antibodies derived from cell-based and solid-phase screening of a phage display library. Two classes of antibodies were found, one directed against the EGF-repeat region that encompasses the ligand-binding domain (LBD), and the second directed against the activation switch of the receptor, the Notch negative regulatory region (NRR). The antibodies are selective for Notch1, inhibiting Jag2-dependent signaling by Notch1 but not by Notch 2 and 3 in reporter gene assays, with EC50 values as low as 5±3 nM and 0.13±0.09 nM for the LBD and NRR antibodies, respectively, and fail to recognize Notch4. While more potent, NRR antibodies are incomplete antagonists of Notch1 signaling. The antagonistic activity of LBD, but not NRR, antibodies is strongly dependent on the activating ligand. Both LBD and NRR antibodies bind to Notch1 on human tumor cell lines and inhibit the expression of sentinel Notch target genes, including HES1, HES5, and DTX1. NRR antibodies also strongly inhibit ligand-independent signaling in heterologous cells transiently expressing Notch1 receptors with diverse NRR “class I” point mutations, the most common type of mutation found in human T-cell acute lymphoblastic leukemia (T-ALL). In contrast, NRR antibodies failed to antagonize Notch1 receptors bearing rare “class II” or “class III” mutations, in which amino acid insertions generate a duplicated or constitutively sensitive metalloprotease cleavage site. Signaling in T-ALL cell lines bearing class I mutations is partially refractory to inhibitory antibodies as compared to cell-penetrating gamma-secretase inhibitors. Conclusions/Significance Antibodies that compete with Notch1 ligand binding or that bind to the negative regulatory region can act as potent inhibitors of Notch1 signaling. These antibodies may have clinical utility for conditions in which inhibition of signaling by wild-type Notch1 is desired, but are likely to be of limited value for treatment of T-ALLs associated with aberrant Notch1 activation.
Collapse
Affiliation(s)
- Miguel Aste-Amézaga
- Department of Biologics Research, Merck Research Laboratories, West Point, Pennsylvania, United States of America
- * E-mail:
| | - Ningyan Zhang
- Department of Biologics Research, Merck Research Laboratories, West Point, Pennsylvania, United States of America
| | - Janet E. Lineberger
- Department of Biologics Research, Merck Research Laboratories, West Point, Pennsylvania, United States of America
| | - Beth A. Arnold
- Department of Biologics Research, Merck Research Laboratories, West Point, Pennsylvania, United States of America
| | - Timothy J. Toner
- Department of Biologics Research, Merck Research Laboratories, West Point, Pennsylvania, United States of America
| | - Mingcheng Gu
- Department of Biologics Research, Merck Research Laboratories, West Point, Pennsylvania, United States of America
| | - Lingyi Huang
- Department of Biologics Research, Merck Research Laboratories, West Point, Pennsylvania, United States of America
| | - Salvatore Vitelli
- Department of Biologics Research, Merck Research Laboratories, West Point, Pennsylvania, United States of America
| | - Kim T. Vo
- Department of Biologics Research, Merck Research Laboratories, West Point, Pennsylvania, United States of America
| | - Peter Haytko
- Department of Biologics Research, Merck Research Laboratories, West Point, Pennsylvania, United States of America
| | - Jing Zhang Zhao
- Department of Biologics Research, Merck Research Laboratories, West Point, Pennsylvania, United States of America
| | - Frederic Baleydier
- Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, United States of America
| | - Sarah L'Heureux
- Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, United States of America
| | - Hongfang Wang
- Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, United States of America
| | - Wendy R. Gordon
- Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, United States of America
| | - Elizabeth Thoryk
- Department of Vaccines, Merck Research Laboratories, West Point, Pennsylvania, United States of America
| | - Marie Blanke Andrawes
- Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, United States of America
| | - Kittichoat Tiyanont
- Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, United States of America
| | - Kimberly Stegmaier
- Department of Pediatric Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, United States of America
- Cancer Program, Broad Institute, Cambridge, Massachusetts, United States of America
| | - Giovanni Roti
- Department of Pediatric Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, United States of America
| | - Kenneth N. Ross
- Cancer Program, Broad Institute, Cambridge, Massachusetts, United States of America
| | - Laura L. Franlin
- Department of Biologics Research, Merck Research Laboratories, West Point, Pennsylvania, United States of America
| | - Hui Wang
- Department of Biologics Research, Merck Research Laboratories, West Point, Pennsylvania, United States of America
| | - Fubao Wang
- Department of Biologics Research, Merck Research Laboratories, West Point, Pennsylvania, United States of America
| | - Michael Chastain
- Department of Molecular Profiling and Pharmacology, Merck Research Laboratories, West Point, Pennsylvania, United States of America
| | - Andrew J. Bett
- Department of Vaccines, Merck Research Laboratories, West Point, Pennsylvania, United States of America
| | - Laurent P. Audoly
- Department of Biologics Research, Merck Research Laboratories, West Point, Pennsylvania, United States of America
| | - Jon C. Aster
- Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, United States of America
| | - Stephen C. Blacklow
- Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, United States of America
| | - Hans E. Huber
- Department of Biologics Research, Merck Research Laboratories, West Point, Pennsylvania, United States of America
| |
Collapse
|
12
|
Baleydier F, Decouvelaere AV, Bergeron J, Gaulard P, Canioni D, Bertrand Y, Lepretre S, Petit B, Dombret H, Beldjord K, Molina T, Asnafi V, Macintyre E. T Cell Receptor Genotyping and HOXA/TLX1 Expression Define Three T Lymphoblastic Lymphoma Subsets which Might Affect Clinical Outcome. Clin Cancer Res 2008; 14:692-700. [DOI: 10.1158/1078-0432.ccr-07-1927] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
13
|
Baleydier F, Galambrun C, Manel AM, Guibaud L, Nicolino M, Bertrand Y. Primary lymphoma of the pituitary stalk in an immunocompetent 9-year-old child. Med Pediatr Oncol 2001; 36:392-5. [PMID: 11241445 DOI: 10.1002/mpo.1094] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- F Baleydier
- Department of Pediatric Hematology, Hôpital Debrousse, Lyon, France
| | | | | | | | | | | |
Collapse
|